Observational analysis reveals potential improvements in diagnostic yield using ctDNA sequencing in NSCLC patients, suggesting a shift in strategy may benefit treatment outcomes.
Key Points
The ctDNA next-generation sequencing method shows potential to enhance diagnostic strategies for advanced NSCLC.
Concordance between standard tissue testing and ctDNA-NGS was 71.2%, with 25.4% showing discordant results.
Assessment of real-world data indicated a possible 6.7% increase in diagnostic yield when ctDNA-NGS is selectively applied.
While promising, ctDNA-NGS faces biological challenges and may not fully replace existing testing methods.